Instem Taps Regulatory Architect to Build AI Future for Pharma

BOSTON, MA – April 15, 2026 – In a strategic move signaling a shift from artificial intelligence hype to regulatory reality, Instem, a leading provider of SaaS solutions for preclinical research, has appointed Dr. Szczepan Baran as its new Chief Scientific Officer. The appointment places a key architect of the emerging regulatory standards for AI and New Approach Methodologies (NAMs) at the helm of Instem's scientific strategy, a move poised to reshape how the pharmaceutical industry validates and submits data for new drugs.

Dr. Baran is not just an industry veteran with leadership experience at Novartis and VeriSIM Life; he is a central figure at the table where the rules for next-generation drug development are being written. His appointment is a clear signal that Instem is betting its future on providing something its customers desperately need: a clear, validated path from innovative science to regulatory approval.

Building the Regulatory Bridge for AI

For years, the promise of AI in drug discovery has been tempered by a critical question: will regulators accept the data? Dr. Baran’s career has been dedicated to answering that question. As co-chair of the FNIH Validation & Qualification Network (VQN), he has worked directly with industry partners and regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to establish the evidentiary standards needed for NAMs—a class of technologies that includes AI-driven in silico modeling—to gain acceptance.

Furthermore, his role co-chairing the 3Rs Collaborative's AI Initiative alongside the U.S. FDA places him at the nexus of technology, translational science, and policy. These are not abstract academic exercises; these initiatives are building the practical frameworks that determine whether an AI-generated model is considered credible for a high-stakes regulatory submission. By bringing Dr. Baran in-house, Instem is effectively embedding the rule-maker into its product development lifecycle.

“The pharmaceutical industry is at a real inflection point, not because AI is new, but because the scientific and regulatory infrastructure to use it responsibly is finally taking shape,” said Dr. Baran. “Instem sits at the right point in the preclinical data lifecycle to turn that shift into submission-ready infrastructure for more patient-relevant drug development. That is what I am here to build.”

This move aims to transform Instem's offerings from powerful research tools into indispensable components of a compliant, submission-ready workflow. The goal is to ensure that when a client uses an Instem platform to generate predictive safety data, that data is built from the ground up to withstand regulatory scrutiny.

Beyond the Hype: A Bet on Validated Science

The market for AI in drug development is crowded and noisy. Companies across the spectrum, from startups to established players like Schrödinger and Certara, are leveraging powerful computational platforms. However, Instem's strategy, underscored by this appointment, is to differentiate itself not on the novelty of its algorithms, but on the rigor of its science and its alignment with regulatory expectations.

“There is no shortage of AI messaging in this market,” noted Vik Krishnan, Chief Executive Officer of Instem. “But what customers need is better science inside the workflow and better judgment at the point of decision.”

This statement directly addresses the core challenges hindering widespread AI adoption in pharma. The “black box” problem, where AI models produce conclusions without clear explanations, remains a major hurdle for trust and validation. Likewise, the quality and integration of training data are persistent concerns that can undermine the reliability of AI-generated insights. The industry is grappling with how to prove that these complex digital tools are not just statistically interesting but biologically and clinically relevant.

Dr. Baran's role at Instem will be to tackle these issues head-on. His focus will be on deepening the scientific layer across the business and embedding AI into day-to-day preclinical execution in a way that generates auditable, defensible evidence. This is a deliberate pivot from selling technology to selling validated outcomes, a crucial distinction in a risk-averse, highly regulated industry.

Strengthening a Critical FDA Partnership

Dr. Baran's appointment is amplified by Instem’s already deep and ongoing collaboration with the U.S. FDA. In March 2026, the company announced a five-year extension of its research agreement with the agency through its Leadscope business unit. This partnership, now set to run through February 2031, focuses on developing predictive toxicology models, curated safety databases, and regulatory decision-support tools.

The synergy is powerful. While Leadscope provides the technical engine for building predictive models in direct collaboration with the FDA, Dr. Baran provides the strategic oversight and deep regulatory insight to ensure these tools meet the emerging qualification pathways he has helped define. This creates a virtuous cycle: the tools Instem builds are informed by its work with the FDA, and its strategic direction is now guided by a leader who helps shape the FDA's own standards.

This dual-pronged approach positions Instem not as a vendor selling to the industry, but as a core partner in the modernization of the entire regulatory ecosystem. It aims to accelerate the adoption of NAMs, which promise to reduce reliance on animal testing by providing more human-relevant data through methods like in silico modeling, organoids, and organs-on-chips. The recent FDA draft guidance on NAM validation, issued in March 2026, highlights the agency's commitment to this transition, creating a significant market opportunity for companies that can provide the necessary validated tools.

By combining its long-standing technical collaboration with the FDA and the strategic leadership of a key regulatory influencer, Instem is making a compelling case that it can help its customers navigate this new landscape more effectively than its competitors. The focus is on building the infrastructure for tomorrow's GLP-compliant, NAM-driven workflows today, providing a tangible advantage for drug developers aiming for faster, safer, and more efficient paths to market.